Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01415713

The Study of Metastatic Pancreatic Adenocarcinoma

Phase I/II Trial of Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in Metastatic Pancreatic Adenocarcinoma

Sponsor: Chang Gung Memorial Hospital

Conditions Metastatic Pancreatic Adenocarcinoma

Interventions S-1,Leucovorin,Oxaliplatin,Gemcitabine

Updated 5 times since 2017 Last updated: May 3, 2016 Started: Mar 31, 2012 Primary completion: Apr 30, 2016 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Metastatic Pancreatic Adenocarcinoma, this trial is completed. The trial is conducted by Chang Gung Memorial Hospital and has accumulated 5 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chang Gung Memorial Hospital
National Cheng-Kung University Hospital
National Health Research Institutes, Taiwan
National Taiwan University Hospital

Data source: National Health Research Institutes, Taiwan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan